Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:1788 |
Name | peritoneal mesothelioma |
Definition | A peritoneum cancer that develops from cells of the mesothelium and is located_in the peritoneum. |
Source | DiseaseOntology.org |
Alt Ids | DOID:0050874 DOID:7954 |
Path | disease disease of cellular proliferation cancer organ system cancer peritoneum cancer peritoneal mesothelioma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00996385 | Phase II | Bortezomib + Oxaliplatin | Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma | Unknown status | USA | 0 |
NCT02399371 | Phase II | Pembrolizumab | Pembrolizumab in Treating Patients With Malignant Mesothelioma | Active, not recruiting | USA | 0 |
NCT02639091 | Phase I | Anetumab ravtansine + Cisplatin + Pemetrexed Disodium | Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors | Completed | USA | ITA | 0 |
NCT02824042 | Phase I | Anetumab ravtansine + Itraconazole Anetumab ravtansine | Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole | Completed | USA | NLD | FRA | ESP | BEL | AUS | 0 |
NCT03054298 | Phase I | HuCART-meso cells Cyclophosphamide | CAR T Cells in Mesothelin Expressing Cancers | Completed | USA | 0 |
NCT03074513 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | Active, not recruiting | USA | 0 |
NCT03212404 | Phase I | Cosibelimab | Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers | Recruiting | NZL | FRA | ESP | AUS | 5 |
NCT03319537 | Phase Ib/II | MLN4924 Cisplatin + MLN4924 + Pemetrexed Disodium | Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma | Terminated | USA | 0 |
NCT03399552 | Phase Ib/II | Avelumab | Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma | Completed | USA | 0 |
NCT03436732 | Phase I | LMB-100 + SVP-rapa | Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma | Terminated | USA | 0 |
NCT03546426 | Phase I | Aldesleukin + Pembrolizumab | Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX) | Unknown status | ITA | 0 |
NCT03608618 | Phase I | MCY-M11 Cyclophosphamide | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | Terminated | USA | 0 |
NCT03717415 | Phase Ib/II | Carboplatin + Rebastinib | A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors | Completed | USA | 0 |
NCT03907852 | Phase Ib/II | Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | Active, not recruiting | USA | CAN | 0 |
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | CAN | 0 |
NCT04840615 | Phase I | Ipilimumab + LMB-100 | Phase I Study of Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma | Terminated | USA | 0 |
NCT05001880 | Phase II | Bevacizumab + Carboplatin + Pemetrexed Disodium Atezolizumab + Bevacizumab + Carboplatin + Pemetrexed Disodium | Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma | Recruiting | USA | 0 |
NCT05041062 | Phase II | Ipilimumab + Nivolumab | A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma | Completed | USA | 0 |
NCT05071014 | Phase I | Pembrolizumab | A Study of Pembrolizumab and Cryoablation in People With Mesothelioma | Completed | USA | 0 |
NCT05337735 | Phase II | XmAb20717 | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers | Suspended | USA | 0 |
NCT05500508 | Phase Ib/II | AMXT1501 + Eflornithine | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Suspended | USA | AUS | 0 |
NCT05568680 | Phase I | SynKIR-110 | SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma | Recruiting | USA | 0 |
NCT06255665 | Phase I | JNJ-79032421 | A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors | Recruiting | ESP | 0 |